Adnan O. Abu-Yousif, Ph.D.
Affiliations: | 2007 | Pharmacology, Toxicology & Therapeutics | University of Kansas, Lawrence, KS, United States |
Area:
Toxicology, OncologyGoogle:
"Adnan Abu-Yousif"Parents
Sign in to add mentor| Curtis D. Klaassen | grad student | 2007 | University of Kansas | |
| (Enhancement of UVB-induced apoptosis by the chemopreventive bioflavonoid apigenin in multiple human keratinocyte models.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Knelson EH, Ivanova EV, Tarannum M, et al. (2022) Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunology Research |
| Khera E, Cilliers C, Smith MD, et al. (2020) Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping. Neoplasia (New York, N.Y.). 23: 210-221 |
| Abu-Yousif AO, Cvet D, Gallery M, et al. (2020) Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-Derived Xenografts. Molecular Cancer Therapeutics |
| Casaletto JB, Geddie ML, Abu-Yousif AO, et al. (2019) MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proceedings of the National Academy of Sciences of the United States of America |
| Gallery M, Zhang J, Bradley DP, et al. (2018) A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo. Plos One. 13: e0191046 |
| Evans CL, Abu-Yousif AO, Park YJ, et al. (2011) Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT. Plos One. 6: e23434 |